Early and late hematologic toxicity following CD19 CAR-T cells

Shalev Fried, Abraham Avigdor, Bella Bielorai, Amilia Meir, Michal J. Besser, Jacob Schachter, Avichai Shimoni, Arnon Nagler, Amos Toren, Elad Jacoby*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Autologous T cells transduced with CD19-directed chimeric antigen receptors have recently been approved by several regulatory agencies for the treatment of relapsed and refractory leukemia and lymphoma, after demonstrating remarkable remission rate in advanced patients. The most common adverse events reported are cytokine-release syndrome (CRS), neurotoxicity, and hematologic toxicity. Here, we focus on early and late cytopenia occurring after CD19 CAR-T cells in 38 patients treated with CD19 CAR-T cells. Neutropenia, thrombocytopenia, and anemia occur frequently (94, 80, and 51%, respectively) after CAR-T cell infusion, and are associated with a biphasic nature, as in 93% of patients hematologic toxicity occurs after 21 days from cell infusion. Late hematologic toxicity was more common in patients with high grade CRS and in patients treated after a recent stem cell transplantation. Interestingly, since these events occur late after the lymphodepleting chemotherapy and after resolution of CRS, we found perturbations in SDF-1 levels to correlate with events of late neutropenia, likely associated with B-cell recovery.

Original languageEnglish
Pages (from-to)1643-1650
Number of pages8
JournalBone Marrow Transplantation
Volume54
Issue number10
DOIs
StatePublished - 1 Oct 2019

Fingerprint

Dive into the research topics of 'Early and late hematologic toxicity following CD19 CAR-T cells'. Together they form a unique fingerprint.

Cite this